| ²é¿´: 2279 | »Ø¸´: 12 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
yalefield½ð³æ (ÎÄ̳¾«Ó¢)
ÀϺºÒ»Ã¶
|
[½»Á÷]
ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]
|
||
|
×÷ÕߣºJingyi ¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾³£ÓÉÎüÑÌÓÕ·¢¡£ ¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£ ¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£ ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2) µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£ ¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£ Note: 1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561. 2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html 3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu |
» ²ÂÄãϲ»¶
294Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
322Çóµ÷¼Á£ºÒ»Ö¾Ô¸ºþÄÏ´óѧ ²ÄÁÏÓ뻯¹¤£¨085600£©£¬ÒѹýÁù¼¶¡£
ÒѾÓÐ14È˻ظ´
282Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
µ÷¼Á
ÒѾÓÐ9È˻ظ´
315Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
wangw2008
½ð³æ (Ö°Òµ×÷¼Ò)
´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1151.1
- É¢½ð: 4
- ºì»¨: 5
- ɳ·¢: 1
- Ìû×Ó: 3441
- ÔÚÏß: 40.6Сʱ
- ³æºÅ: 322304
- ×¢²á: 2007-03-11
- רҵ: ҩ

2Â¥2007-12-19 07:07:49
¶¹¸ç
Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)
ÖÆÁ£ÄÜÊÖ
- PhEPI: 15
- Ó¦Öú: 272 (´óѧÉú)
- ¹ó±ö: 16.651
- ½ð±Ò: 26136.9
- É¢½ð: 16691
- ºì»¨: 111
- ɳ·¢: 8
- Ìû×Ó: 4243
- ÔÚÏß: 1037.6Сʱ
- ³æºÅ: 317112
- ×¢²á: 2007-03-04
- ÐÔ±ð: GG
- רҵ: ÖÐÒ©ÖÆ¼Á

3Â¥2007-12-19 14:00:23
![]() ![]() ![]() |
4Â¥2007-12-19 14:13:57
![]() ![]() ![]() ![]() ![]() |
5Â¥2007-12-19 15:05:12
haplinder
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 209
- Ìû×Ó: 2730
- ÔÚÏß: 26·ÖÖÓ
- ³æºÅ: 50928
- ×¢²á: 2004-07-15
- ÐÔ±ð: GG
- רҵ: ¾«Éñ²¡Ñ§
6Â¥2008-01-17 16:47:31
WANTTOKNOW
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ½ð±Ò: 425.5
- É¢½ð: 545
- ºì»¨: 6
- Ìû×Ó: 2685
- ÔÚÏß: 34.7Сʱ
- ³æºÅ: 91973
- ×¢²á: 2005-09-07
- רҵ: ¹¤³Ì¹ÜÀí
7Â¥2008-01-17 17:16:52
xjxlovelxl
ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)
CA-FANS
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 2.962
- ½ð±Ò: 1168
- É¢½ð: 5254
- ºì»¨: 3
- Ìû×Ó: 5985
- ÔÚÏß: 116Сʱ
- ³æºÅ: 291151
- ×¢²á: 2006-10-28
- ÐÔ±ð: MM
- רҵ: ѪҺϵͳ¼²²¡ÕïÁÆÐ¼¼Êõ
- ¹ÜϽ: Óн±ÎÊ´ð

8Â¥2008-01-17 17:17:58
jack_ss
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 218.5
- Ìû×Ó: 95
- ÔÚÏß: 4.8Сʱ
- ³æºÅ: 229113
- ×¢²á: 2006-03-25
- ÐÔ±ð: GG
- רҵ: ÖÆÒ©
9Â¥2008-01-17 18:37:31
bmwfengyun
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
СÆòؤ
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 23534.2
- Ìû×Ó: 1389
- ÔÚÏß: 171.1Сʱ
- ³æºÅ: 252581
- ×¢²á: 2006-05-20
- ÐÔ±ð: GG
- רҵ: ÖÐҩѧÆäËû¿ÆÑ§ÎÊÌâ

10Â¥2008-01-18 09:03:44














»Ø¸´´ËÂ¥

